Press releasePRNewswire
Silence Therapeutics
SLN · OTC
$19.61+$0.03 (+0.15%)TodayMarket closed ·
Prev close $19.58
Latest news
- Press releasePRNewswire
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
- NewsAvi Kapoor
Nasdaq Jumps Over 1% As Tech Stocks Gain: Investor Sentiment Improves, Greed Index Remains In ‘Extreme Fear’ Zone
- NewsShivdeep Dhaliwal
Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today
- NewsAvi Kapoor
Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsVandana Singh
Why Is Silence Therapeutics Stock Skyrocketing Monday?
- NewsAvi Kapoor
Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday
- NewsAvi Kapoor
Nasdaq Surges Over 1%; Fifth Third Bancorp Earnings Top Views
- Press releaseBusiness Wire
SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders
- Press releaseBusiness Wire
Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset
- Press releaseBusiness Wire
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
- NewsAvi Kapoor
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
- Press releaseBusiness Wire
Silence Therapeutics to Participate in Three September Investor Conferences
- Press releaseBusiness Wire
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
- Press releaseBusiness Wire
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
- Press releaseBusiness Wire
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releaseGlobe Newswire
The Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major Milestones
- NewsVandana Singh
Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'
- NewsAvi Kapoor
Varex Imaging Posts Upbeat Q3 Earnings, Joins Bowman Consulting, MarineMax And Other Big Stocks Moving Higher On Monday
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseBusiness Wire
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
- Press releaseBusiness Wire
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
- NewsAvi Kapoor
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket
- Press releaseBusiness Wire
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
- NewsVandana Singh
This $300 Million Biotech May Be Deeply Mispriced: Analyst
- NewsVandana Singh
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
- Press releaseBusiness Wire
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
- Press releaseBusiness Wire
Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
- Press releaseBusiness Wire
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
- Press releaseBusiness Wire
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
- News
Silence Therapeutics Q4 Earnings Assessment
- Press releaseBusiness Wire
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.